News

Grenova to Invest $10.6M to Expand Operations in Richmond

Grenova Inc., a Virginia-based sustainable biotech firm that designs, develops, and manufactures devices that wash and sterilize contaminated pipette tips for reuse, will invest $10.6 million to expand in the City of Richmond. The company will relocate its operations from Manchester to a larger facility in Scott’s Addition and increase capacity with new production lines in response to the shortage of pipette tips used for COVID-19 testing. Governor Northam joined company leaders at the site of Grenova’s future location at 1900 Ellen Road to celebrate the project, which will add 250 new jobs over the next three years.

“We are thrilled to celebrate this homegrown sustainable biotech firm expanding and adding to its workforce in Richmond,” said Governor Northam. “It is remarkable to see Virginia’s innovative life sciences businesses quickly adapt and respond to critical needs as we fight this pandemic. Grenova is an emerging industry leader that has achieved exponential growth in a short time, and I applaud the company for leveraging its technology and expertise to address a global shortage and reduce environmental waste.”

Founded in Richmond in 2014, Grenova’s mission is to help lower costs and reduce biohazard waste by delivering groundbreaking approaches in dealing with plastic consumables. The company’s product, Tipnovus™ enables laboratories to wash and sanitize pipette tips for reuse numerous times, cutting associated consumable costs by up to 96 percent. Ten pipette tips are used to fully conduct one COVID-19 test, resulting in a worldwide shortage of the plastic consumable. Grenova’s technology allows healthcare systems to safely wash and reuse the pipette tips used for testing, which has helped to end pipette tip shortages and improve access to COVID-19 testing while making labs more environmentally friendly. Due to demand for Grenova’s products, the company has quadrupled in size in the last year. Grenova sells products from its Richmond facility to laboratories and distributors across the United States, as well as in Europe and Asia.

“This expansion project is an important win that will create 250 new, high-quality jobs and help improve Richmond’s standing as a life sciences hub,” said Secretary of Commerce and Trade Brian Ball. “Grenova is a great success story for the Commonwealth, and we are confident the region will continue to provide the business climate and workforce needed for years to come.”

“Our growth is a sign that the world is ready to rethink, reimagine, and reinvent the way plastic consumables like pipette tips are washed and reused within the life sciences industry and beyond,” said Ali Safavi, Founder and CEO of Grenova. “We’re proud to make our bold solution possible from our expanded headquarters in Richmond thanks to the Commonwealth’s thriving ecosystem of world-class talent, resources, and infrastructure.”

The Virginia Economic Development Partnership worked with the City of Richmond to secure the project for the Commonwealth. Grenova Inc. is eligible to receive state benefits from the Virginia Enterprise Zone Program, administered by the Virginia Department of Housing and Community Development, and funding and services to support the company’s employee recruitment and training activities will be provided through the Virginia Jobs Investment Program.

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these